ANEB
Income statement / Annual
Last year (2024), Anebulo Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Anebulo Pharmaceuticals, Inc.'s net income was -$8.20 M.
See Anebulo Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$3.55 M
|
$5.60 M
|
$2.96 M
|
$2.27 M
|
$150,000.00
|
| General & Administrative
Expenses |
$4.76 M
|
$6.18 M
|
$3.87 M
|
$1.34 M
|
$140,106.00
|
| Selling & Marketing
Expenses |
$4,800.00
|
$0.00
|
$0.00
|
$0.00
|
$23,210.00
|
| Selling, General &
Administrative Expenses |
$4.76 M
|
$6.18 M
|
$3.87 M
|
$1.34 M
|
$23,351.00
|
| Other Expenses |
$0.00 |
-$41,146.00 |
-$1,777.00 |
-$1,344.00 |
$0.00 |
| Operating Expenses |
$8.31 M |
$11.78 M |
$6.83 M |
$3.61 M |
$173,351.00 |
| Cost And Expenses |
$8.31 M |
$11.78 M |
$6.83 M |
$3.61 M |
$173,351.00 |
| Interest Income |
$97,792.00 |
$92,407.00 |
$7,332.00 |
$1,020.00 |
$7.72 |
| Interest Expense |
$0.00 |
$0.00 |
$7,332.00 |
$11,767.00 |
$1,286.00 |
| Depreciation &
Amortization |
$258,282.00
|
$11.78 M
|
$6.83 M
|
$3.61 M
|
$1.04 M
|
| EBITDA |
-$8.05 M
|
-$11.78 M
|
$5,555.00
|
-$30.24 M
|
-$173,350.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$107,052.00
|
$51,261.00
|
$5,555.00
|
-$26.64 M
|
-$1,287.00
|
| Income Before Tax |
-$8.20 M |
-$11.73 M |
-$6.83 M |
-$30.25 M |
-$174,637.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$104,190.60 |
-$12,887.00 |
$10,747.00 |
-$1,040.11 |
| Net Income |
-$8.20 M |
-$11.73 M |
-$6.81 M |
-$30.26 M |
-$174,637.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.32 |
-0.47 |
-0.29 |
-1.3 |
-0.0074 |
| EPS Diluted |
-0.32 |
-0.47 |
-0.29 |
-1.3 |
-0.0074 |
| Weighted Average Shares
Out |
$25.82 M
|
$25.07 M
|
$23.34 M
|
$23.34 M
|
$23.72 M
|
| Weighted Average Shares
Out Diluted |
$25.82 M
|
$25.07 M
|
$23.34 M
|
$23.34 M
|
$23.72 M
|
| Link |
|
|
|
|
|
